I-Semaglutide iyi-synthetic glucagon-like peptide-1 (GLP-1) receptor agonist esebenza isikhathi eside, eyenzelwe ukwelapha uhlobo lwesifo sikashukela sohlobo 2 nokukhuluphala. Iguquliwe ngokwesakhiwo ukuze imelane nokuwohloka kwe-enzymatic futhi ithuthukise isigamu sempilo, i-Semaglutide ivumela i-dosing elula kanye ngesonto, ithuthukisa kakhulu ukunamathela kwesiguli.
EyethuSemaglutide APIikhiqizwa ngenqubo yokwenziwa ngokugcwele, esusa izingozi ezihlobene nezinhlelo zokubonisa izinto eziphilayo, njengeprotheni yeseli eliphethe noma ukungcoliswa kwe-DNA. Yonke inqubo yokukhiqiza isithuthukisiwe futhi yaqinisekiswa esikalini sekhilogremu, ihlangabezana nezimfuneko zekhwalithi eziqinile ezishiwo kumhlahlandlela we-FDA wango-2021 mayelana nokuhanjiswa kwe-ANDA kwezidakamizwa ze-peptide zokwenziwa ezihlanzekile.
I-Semaglutide ilingisa i-GLP-1 yomuntu, i-incretin hormone edlala indima ebalulekile kumetabolism ye-glucose. Isebenza ngezindlela eziningi ze-synergistic:
Ikhuthaza ukukhiqizwa kwe-insulinngendlela encike ku-glucose
Ivimbela ukukhiqizwa kwe-glucagon, yehlisa ukuphuma kwe-glucose ku-hepatic
Ibambezela ukuphuma kwesisu, okuholela ekulawuleni okuthuthukisiwe kwe-postprandial glycemic
Yehlisa isifiso sokudla kanye nokudla amandla, ukusekela ukulahlekelwa isisindo
Izifundo ezibanzi zemitholampilo (isb, i-SUSTAIN ne-STEP izivivinyo) zibonise ukuthi i-Semaglutide:
Yehlisa kakhulu i-HbA1c kanye nezinga le-glucose esheshayo ezigulini ezinesifo sikashukela sohlobo 2
Ikhuthaza ukwehla kwesisindo esiningi nokuqhubekayo kubantu abakhuluphele noma abakhuluphele
Yehlisa izimpawu zengozi yenhliziyo nemithambo yegazi njengomfutho wegazi nokuvuvukala
Ngephrofayili yokuphepha evumayo kanye nezinzuzo ezibanzi ze-metabolic, i-Semaglutide isiphenduke i-GLP-1 RA yomugqa wokuqala kushukela kanye nokwelapha okulwa nokukhuluphala. Inguqulo yethu ye-API igcina ukwethembeka kwesakhiwo okuphezulu kanye namazinga aphansi okungcola (≤0.1% ukungcola okungaziwa kwe-HPLC), iqinisekisa ukuvumelana okuhle kakhulu kwezemithi.